Zimmer Biomet (ZBH) Earns “Overweight” Rating from Cantor Fitzgerald

Zimmer Biomet (NYSE:ZBH)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued on Friday.

A number of other analysts also recently issued reports on ZBH. Zacks Investment Research raised Zimmer Biomet from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. SunTrust Banks reissued a “buy” rating and issued a $136.00 target price on shares of Zimmer Biomet in a research report on Monday, October 2nd. Piper Jaffray Companies downgraded Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 2nd. BMO Capital Markets decreased their target price on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a research report on Thursday, November 2nd. Finally, Morgan Stanley reduced their price target on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating for the company in a research report on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Zimmer Biomet presently has a consensus rating of “Buy” and a consensus price target of $137.42.

Shares of Zimmer Biomet (NYSE ZBH) opened at $125.98 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. Zimmer Biomet has a 52-week low of $103.62 and a 52-week high of $133.49. The stock has a market capitalization of $25,256.49, a price-to-earnings ratio of 39.62, a price-to-earnings-growth ratio of 1.94 and a beta of 1.15.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. During the same period in the prior year, the business earned $1.79 earnings per share. The business’s quarterly revenue was down .8% compared to the same quarter last year. equities analysts predict that Zimmer Biomet will post 8.03 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of ZBH. Longview Partners Guernsey LTD boosted its stake in Zimmer Biomet by 17.7% during the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after buying an additional 1,128,973 shares during the period. Koch Industries Inc. boosted its stake in Zimmer Biomet by 49,697.3% during the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after buying an additional 1,038,674 shares during the period. Alyeska Investment Group L.P. boosted its stake in Zimmer Biomet by 249.3% during the third quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock valued at $119,417,000 after buying an additional 727,925 shares during the period. BlackRock Inc. lifted its stake in Zimmer Biomet by 4.1% during the second quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock worth $2,236,657,000 after purchasing an additional 679,080 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Zimmer Biomet by 20.2% during the second quarter. Northern Trust Corp now owns 4,010,274 shares of the medical equipment provider’s stock worth $514,919,000 after purchasing an additional 673,079 shares during the last quarter. 85.92% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Zimmer Biomet (ZBH) Earns “Overweight” Rating from Cantor Fitzgerald” was posted by Equities Focus and is the property of of Equities Focus. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.equitiesfocus.com/2018/01/07/zimmer-biomet-zbh-earns-overweight-rating-from-cantor-fitzgerald.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply